Clinical Cancer Research · 2008 · 38 citations · 42 references
MedicineCancer BiologyOncologyGene ExpressionMetastasisMolecular OncologyAngiogenesisAngiogenesis In CancerHepatocellular CarcinomaLiver CancerLiver MetastasisRna InterferenceHepatocellular Carcinoma MetastasisHepatocellular Carcinoma PathogenesisHypoxia-inducible Factor RegulationHypoxia-inducible Factor SignalingHypoxia-inducible SignalingMetastatic SignalingTumor-node-metastasis StagingVascular Endothelial Growth Factor
PURPOSE: We aimed to explore the molecular and biological functions of Inhibitor of DNA binding/differentiation 2 (ID2), which was found to be responsible for portal vein invasion of hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: We measured ID2 mRNA levels in 92 HCC patients by real-time reverse transcription-PCR and examined the relation to clinicopathologic features. To clarify the precise roles of ID2, we did in vitro analysis with expression vectors and small interfering RNAs. Effects of ID2 on cell invasive potential and expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1alpha were analyzed by Matrigel-coated invasion chamber, ELISA, and Western blot analysis, respectively. RESULTS: ID2 mRNA level correlated inversely with portal vein invasion (P < 0.001), tumor-node-metastasis stage (P < 0.001), tumor size (P < 0.001), and early intrahepatic recurrence (P < 0.05). When limited to a cohort of hepatitis C virus-related HCCs, patients with low levels of ID2 had significantly shorter disease-free survival time than those with high levels of ID2. Invasive potential of cells transfected with ID2 expression vector was lower than that of empty vector-transfected cells. Cells overexpressing ID2 also showed decreased VEGF secretion and hypoxia-inducible factor-1alpha protein levels. The results of ID2-knockdown experiments were opposite to those of ID2 overexpression experiments. CONCLUSIONS: On the basis of our clinical and in vitro data, we suggest that ID2 plays a significant role in the metastatic process during progression of HCC. This action might be explained, at least in part, by altered cell mobility due to decreased secretion of VEGF.
42
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
The protein Id: A negative regulator of helix-loop-helix DNA binding proteins
Robert Benezra, Robert L. Davis, Daniel Lockshon et al. · Cell · 1990 · 2.3K citations
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
David Lyden, Alison Z. Young, David Zagzag et al. · Nature · 1999 · 934 citations
Medicine, Cancer Biology, Oncology +12
Simplified Staging for Hepatocellular Carcinoma
J.N. Vauthey · Journal of Clinical Oncology · 2002 · 626 citations